Publications

2018

Stopsack KH, Gonzalez-Feliciano AG, Peisch SF, Downer MK, Gage RA, Finn S, et al. A Prospective Study of Aspirin Use and Prostate Cancer Risk by Status. Cancer Epidemiol Biomarkers Prev. 2018;27(10):1231-1233.
Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, et al. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018;39(12):1431-1437.
Vaisitti T, Braggio E, Allan JN, Arruga F, Serra S, Zamò A, et al. Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses. Cancer Res. 2018;78(13):3413-3420.
Patel N, Cricco-Lizza E, Kasabwala K, Xu C, Robinson BD, Khani F, et al. The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy. Eur Urol Oncol. 2018;1(4):263-267.
Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A, et al. Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma. 2018;59(12):2829-2835.
Ellis L, Loda M. LSD1: A single target to combat lineage plasticity in lethal prostate cancer. Proc Natl Acad Sci U S A. 2018;115(18):4530-4531.
Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560(7719):499-503.
Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pertega-Gomes N, et al. MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(2):201-207.
Kyriakides PW, Inghirami G. Are we ready to take full advantage of patient-derived tumor xenograft models? Hematol Oncol. 2018;36(1):24-27.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700